Corroborative investigations with subsets of CRC-PDOs revealed, that independently from their mutational setting, all tested PDOs responded at similar extent to the MKK3 depletion (Fig. 6B), therefore suggesting that the MKK3 targeting might cover a wider therapeutic opportunity in CRC. Here, MAP2K3 is linked to colorectal carcinoma.